文献速递血脂与心血管预防

降脂靶点的演变:从分子机制到转化意义

The evolving landscape of targets for lipid lowering: from molecular mechanisms to translational implications.
PubMed 文献 · Eur Heart J · 2025-01-01

该综述指出,LDL-C是降脂治疗的主要靶点,但甘油三酯、载脂蛋白B和脂蛋白(a)对残余心血管风险同样重要。文章系统梳理了现有及新兴降脂靶点的分子机制,包括他汀、贝派地酸、PCSK9抑制剂、ANGPTL3、apoC-III和CETP等,并讨论了针对Lp(a)的反义疗法等新策略,为耐药或特定脂质异常患者提供新选择。

要点

  • LDL-C是主要降脂靶点,但甘油三酯、apoB和Lp(a)与残余心血管风险相关。
  • 新兴靶点包括ANGPTL3、apoC-III和CETP,抑制ANGPTL3可不依赖LDL受体降低甘油三酯和LDL-C。
  • 针对Lp(a)的反义疗法等策略正在研究中,旨在证明其心血管获益。

核心结论

  • 降脂靶点领域不断发展,为现有治疗耐药或特定脂质谱异常患者提供新策略。

研究设计与样本

  • 综述,检索范围未明确报告。

主要发现

  • 他汀抑制HMG-CoA还原酶,减少胆固醇生物合成并增加肝脏LDL受体表达。
  • 贝派地酸抑制ATP柠檬酸裂解酶,选择性作用于肝脏,减少肌肉相关副作用。
  • PCSK9抑制剂防止LDL受体降解,依折麦布限制肠道胆固醇吸收。
  • 抑制ANGPTL3可不依赖LDL受体降低甘油三酯和LDL-C;抑制apoC-III可激活脂蛋白脂肪酶,促进富含甘油三酯颗粒分解代谢。
  • CETP抑制增加含apoB脂蛋白的分解代谢;针对Lp(a)的反义疗法等研究正在进行。

关键数值与推荐

  • 原文未报告具体数值标准或推荐条款。

临床怎么用

  • 对现有降脂治疗耐药或具有特定脂质谱异常的患者,可关注新兴靶点相关策略。

局限性

  • 原文未报告。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Cardiovascular disease remains a major global health challenge, with dyslipidaemia being a key modifiable risk factor. While low density lipoprotein cholesterol (LDL-C) is the primary target for lipid-lowering therapies, recent evidence highlights the importance of triglycerides, apolipoprotein B (apoB), and lipoprotein(a) [Lp(a)] for residual cardiovascular risk. Current lipid-lowering therapies target key enzymes and proteins involved in cholesterol and lipid metabolism. Statins inhibit HMG-CoA reductase, reducing cholesterol biosynthesis and increasing LDL receptor (LDLR) expression in the liver. Bempedoic acid inhibits ATP citrate lyase, the enzyme upstream of HMG-CoA reductase in the mevalonate pathway, offering an alternative to statins by selectively acting in the liver, minimizing muscle-related side effects. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors [evolocumab, alirocumab, inclisiran, lerodalcibep, and enlicitide decanoate (MK0616)] prevent LDLR degradation, while ezetimibe limits intestinal cholesterol absorption. Emerging lipid-lowering targets include angiopoietin-like 3 protein (ANGPTL3) and apolipoprotein C-III (apoC-III). Inhibiting ANGPTL3 reduces both triglycerides and LDL-C independently of LDL receptor. Inhibition of apoC-III unleashes lipoprotein lipase (LPL) activity, promoting triglyceride-rich particle catabolism, even in complete LPL deficiency. Cholesteryl ester transfer protein (CETP) inhibition also increases the catabolism of apoB-containing lipoproteins. Ongoing research into strategies to reduce Lp(a), primarily but not exclusively through antisense therapies, aims to demonstrate the cardiovascular benefits of targeting this lipoprotein. In summary, the field of targets for lipid and lipoprotein lowering is constantly evolving and offers new strategies for patients resistant to current therapies or with specific lipid profile abnormalities.

来源:Eur Heart J,查看原文。版权归原作者所有。

引用

  1. Ballantyne CM, Norata GD. The evolving landscape of targets for lipid lowering: from molecular mechanisms to translational implications. Eur Heart J. 2025. PMID: 40911366. doi:10.1093/eurheartj/ehaf606

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。